BioSpace News Archive

Repligen Corporation (NASDAQ:RGEN) today announced the appointment of healthcare industry executive Carrie Eglinton Manner to its Board of Directors.

ContraFect Corporation, a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents, including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announced the appointment of Lishan Aklog, M.D. to the Company’s board of directors.

Extendicare Inc. announced that it has declared a cash dividend of C$0.04 per common share of the Company for the month of June 2020, which is payable on July 15, 2020 to shareholders of record at the close of business on June 30, 2020.

Patient enrollment and data generation remain on schedule with 13 patients having received CUE-101 to date and enrollment continues per protocol to identify a recommended Phase 2 dose Dose-proportional increases in drug exposure combined with observations demonstrating pharmacodynamic biomarkers in peripheral blood and clinical data from scans bolsters confidence in potential for attractive therapeutic window CAMBRIDGE, Mass., June 15, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (

Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced the appointment of Clinton Musil as its new chief financial officer, effective July 1, 2020. “Mr. Musil brings a deep understanding of capital markets, financial strategy and M&A experience to the Company and we are delighted to have him join Catalyst’s executive leadership team,” said Nassim Usman, Ph.D., president and chief executive officer of Catalyst. “His busine

Janpix Inc., a biotechnology company developing monovalent small molecule protein degraders as novel therapeutics, announced the company will present preclinical data showing the characterization of novel, highly selective and potent monovalent degraders of STAT3 & STAT5 proteins.

Beyond Air, Inc. announced the publication of its scientific article, “Inhaled nitric oxide therapy in acute bronchiolitis: A multicenter randomized clinical trial” in Scientific Reports, an online peer-reviewed journal from the publishers of Nature.

Soliton, Inc., (Nasdaq: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary platform technology, today announced that new positive data from the company’s pivotal cellulite clinical trial was presented in an oral presentation via the American Academy of Dermatology (AAD) 2020 VMX Virtual Conference on June 12, 2020.

MBio Diagnostics today announced delivery to the U.S. Department of Defense with funding for this effort provided by the Defense Health Program through the Joint Program Executive Office as part of a development program for a

Puzzle Medical Devices Inc., announces the closure of its first convertible debenture financing round led by Canadian entrepreneur Pascal Labrecque.